Treatment options for
metastatic urothelial carcinoma:

Patient case studies

Urothelial carcinoma is one of the most common malignancies worldwide. For patients with metastatic urothelial carcinoma (mUC), systemic chemotherapy has been the standard of care for many years but the development of new therapeutics is starting to expand treatment options. Here, you are invited to participate in this three-part case study series, which looks at how to manage patients with mUC.

  • In the first case study, we follow a patient who is not eligible to receive cisplatin-based chemotherapy and look at other available options in this situation.

  • In the second case study, we look at first-line therapy for cisplatin-eligible patients and the following standard immune checkpoint inhibitor maintenance regimen.

  • In the final case study, we consider three patients whose disease has progressed after first- and/or second-line therapy, and look at available options and the clinical data behind them for these situations.

Each case study will take up to 15 minutes to complete. Review the evidence, test your knowledge through these case-based self-assessments and help guide your everyday clinical practice.

Case studies

Case 1: First-line therapy for cisplatin-ineligible patients

Professor Aristotle Bamias presents an interactive case study on selecting the most adequate first-line treatment option for a cisplatin-ineligible patient.

Case 2: First-line therapy for cisplatin-eligible patients followed by maintenance therapy

Professor Jens Bedke presents an interactive case study on selecting the most adequate first-line treatment option for cisplatin-eligible patients and explains the standard maintenance therapy.

Case 3: Second- and subsequent lines of treatment for patients with mUC

Professor Cora Sternberg presents an interactive case study which follows patients whose disease has progressed after first- and/or second-line therapy and considers available treatment options for these situations.

Login to access these case studies

  • This field is for validation purposes and should be left unchanged.

About this activity

Professor Aristotle Bamias

Professor Aristotle Bamias

Professor Aristotle Bamias is Professor of Therapeutics-Internal Medicine-Oncology at the Medical School University of Athens, Greece. He studied Medicine at the Medical School of the University of Athens, obtained his PhD at the University of London and served as Lecturer in Medical Oncology at St Bartholomew’s Hospital, London.

Professor Bamias’ main research focus in oncology is urogenital and gynecological tumors. He has authored or co-authored more than 290 original papers and reviews in peer-reviewed journals including the N Engl J Med, Lancet, Lancet Oncology and J Clin Oncol.

A founding member and Chair of the Hellenic Genito-Urinary Cancer Group (HGUCG), Professor Bamias is also a member of other organizations, such as the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) and the Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators. Since 2012, Professor Bamias has been a member of the European Society of Medical Oncology (ESMO) Faculty for Genitourinary Cancer, and he chaired this group from 2016 to 2020. He has been part of several international advisory boards and steering committees of international trials.

His molecular and clinical research has won multiple awards, stipends and prizes, and he has authored and co-authored more than 200 publications.

Disclosures

Professor Bamias has previously received honoraria, and/or advisory, research support from BMS, MSD, Roche, Pfizer, AstraZeneca, Janssen, and Ipsen.



Professor Jens Bedke

Professor Jens Bedke

Professor Jens Bedke is Vice Chairman at the Department of Urology, University of Tübingen, Germany. Professor Bedke’s main research areas include uro-oncology, tumor immunology and metabolomics. He has a special interest in the research of renal cell cancer and bladder carcinoma, with a focus on translational studies with immune-targeting agents. His clinical focus is the surgical therapy of uro-oncologic tumors, with a special emphasis on robotic and open radical prostatectomy, nephron-sparing surgery and cystectomy. He has more than 200 peer-reviewed publications in the N Engl J Med, Lancet and Lancet Oncology. Professor Bedke additionally coordinates the Comprehensive Cancer Center at Tübingen University. He actively participates in several clinical trials as Principal Investigator, including the current checkpoint inhibitory trials in perioperative treatment of bladder and metastatic kidney carcinoma. A member of several national and international societies, including the European Association of Urology (EAU), American Urological Association (AUA) and European Society for Medical Oncology (ESMO), Professor Bedke’s main goal is to integrate the different aspects of specialized surgical care, dedicated medical oncology, and innovative scientific research towards a patient-centered translational treatment.

Disclosures

Professor Bedke has previously received honoraria for speaker, consultancy or advisory roles from AstraZeneca, Astellas, BMS, Eisai, Ipsen, MSD, Novartis, Roche, EUSA Pharma, Nektar and Pfizer; and institutional financial interests (paid directly to his institution) from Eisai, Ipsen, MSD, Novartis, Roche and Pfizer.



Professor Cora Sternberg

Professor Cora Sternberg

Cora Sternberg is Professor of Medicine and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine, Meyer Cancer Center, New York-Presbyterian, New York, USA. She graduated from the University of Pennsylvania (undergraduate and medical schools), completed her fellowship and was on the staff at Memorial Sloan Kettering Cancer in New York. Professor Sternberg is an internationally respected leader in the fields of medical oncology and urological malignancies and a recognized expert in the area of new drug development. She is particularly known for her influential work in bladder cancer and for her publications on novel therapies for prostate cancer and targeted agents in renal cell carcinoma. She has been Principal Investigator for numerous studies, and is an internationally respected researcher who has lectured extensively at universities and cancer symposia worldwide. Professor Sternberg has published over 400 articles in peer-reviewed publications, including more than 100 first-authored articles. She has co-edited six textbooks, guest-edited six others and published over 80 book chapters. She is also Associate Editor and editorial board member of several International journals.

Disclosures

Professor Sternberg has previously received consultancy fees from Pfizer, MSD, Merck, AstraZeneca, Astellas, Sanofi-Genzyme, Roche-Genentech, Incyte, BMS, Foundation Medicine, Immunomedics now Gilead, Medscape, UroToday, CCO Clinical, Janssen and NCI.

Case 1: First-line therapy for cisplatin-ineligible patients

After completing this case study, you will be able to:

  • Discuss available options for first-line treatment in patients who are ineligible to receive cisplatin-based chemotherapy
  • Understand clinical data behind new therapy options for first-line treatment in patients who are ineligible to receive cisplatin-based chemotherapy
  • Identify the best treatment strategy based on individual patient characteristics



Case 2: First-line therapy for cisplatin-eligible patients followed by maintenance therapy

After completing this case study, you will be able to:

  • Discuss the standard of care in first line for patients with mUC who are eligible for cisplatin-based chemotherapy
  • Understand the clinical data supporting immune checkpoint inhibitor (ICI) maintenance therapy after first-line treatment in patients with mUC



Case 3: Second- and subsequent lines of treatment for patients with mUC

After completing this case study, you will be able to:

  • Discuss available options for second- and subsequent lines of treatment in patients whose disease has progressed after first line
  • Understand clinical data behind new therapy options for second- and subsequent lines of treatment
  • Identify the best treatment strategy based on individual patient characteristics

This independent programme is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

All content has been developed independently by Springer Healthcare IME, in conjunction with an expert Faculty.

Keep up-to-date with Medicine Matters Oncology eAlerts